482 results on '"Hogarty, Michael D"'
Search Results
52. Expanding MYCN’s Reach in Oncogenic Transcription
53. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study
54. Stage 4S Neuroblastoma: Molecular, Histological and Immunohistochemical Characteristics and Presence of Two Distinct Patterns of MYCN Protein Overexpression: A Report from the Children’s Oncology Group
55. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
56. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
57. Neuroblastoma
58. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
59. A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma
60. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance
61. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Childrenʼs Oncology Group
62. Peripheral Neuroblastic Tumors With Genotype–Phenotype Discordance: A Report From the Childrenʼs Oncology Group and the International Neuroblastoma Pathology Committee
63. Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions
64. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers
65. Epigenetic state determines inflammatory sensing in neuroblastoma
66. MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells
67. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
68. The Stress Protein BAG3 Stabilizes Mcl-1 and Promotes Cancer Survival and Chemo-Resistance: 286
69. Pediatric Horner Syndrome
70. Stage 4S Neuroblastoma
71. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
72. Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients ≥18 months with unfavorable histology and without MYCN amplification: A Children’s Oncology Group (COG) report.
73. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
74. Novel BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers
75. The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur
76. Stabilization of Antiapoptotic Mcl-1 by the Hsp70 co-chaperone BAG3 in Cancer: 121
77. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG
78. Influence of Neuroblastoma Stage on Serum-Based Detection of Mycn Amplification
79. Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas
80. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma
81. Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma
82. Cutaneous metastatic chordoma with concomitant tuberous sclerosis
83. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
84. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification
85. Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study
86. Longitudinal evaluation of cardiopulmonary performance during exercise after bone marrow transplantation in children
87. Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
88. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma
89. A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.
90. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
91. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression--A Report From the Children's Oncology Gr.
92. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
93. Mutations in PIK3CA are infrequent in neuroblastoma
94. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
95. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
96. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System
97. The challenge of defining “ultra-high-risk” neuroblastoma
98. Abstract IA18:MYCNamplification andATRXmutations are incompatible in neuroblastoma
99. Abstract PR11: Synthetic lethality between ATRX mutations and MYCN amplification in neuroblastoma
100. Abstract 4137: Inhibition of protein synthesis with polyamine depletion in high-risk neuroblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.